Literature DB >> 27190368

Chronicity following ischaemia-reperfusion injury depends on tubular-macrophage crosstalk involving two tubular cell-derived CSF-1R activators: CSF-1 and IL-34.

Maria Dolores Sanchez-Niño1, Ana Belen Sanz1, Alberto Ortiz2.   

Abstract

Two structurally unrelated ligands activate the macrophage colony stimulating factor receptor (CSF-1R, c-fms, CD115): M-CSF/CSF-1 and interleukin-34 (IL-34). Both ligands promote macrophage proliferation, survival and differentiation. IL-34 also activates the protein-tyrosine phosphatase ζ receptor (PTP-ζ, PTPRZ1). Both receptors and cytokines are increased during acute kidney injury. While tubular cell-derived CSF-1 is required for kidney repair, Baek et al (J Clin Invest 2015; 125: 3198-3214) have now identified tubular epithelial cell-derived IL-34 as a promoter of kidney neutrophil and macrophage infiltration and tubular cell destruction during experimental kidney ischaemia-reperfusion, leading to chronic injury. IL-34 promoted proliferation of both intrarenal macrophages and bone marrow cells, increasing circulating neutrophils and monocytes and their kidney recruitment. Thus, injured tubular cells release two CSF-1R activators, one (CSF-1) that promotes tubular cell survival and kidney repair and another (IL-34) that promotes chronic kidney damage. These results hold promise for the development of IL-34-targeting strategies to prevent ischaemia-reperfusion kidney injury in contexts such as kidney transplantation. However, careful consideration should be given to the recent characterization by Bezie et al. (J Clin Invest 2015; 125: 3952-3964) of IL-34 as a T regulatory cell (Treg) cytokine that modulates macrophage responses so that IL-34-primed macrophages potentiate the immune suppressive capacity of Tregs and promote graft tolerance.
© The Author 2016. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Entities:  

Keywords:  inflammation; kidney; macrophages; tolerance; transplantation

Mesh:

Substances:

Year:  2016        PMID: 27190368     DOI: 10.1093/ndt/gfw026

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  6 in total

1.  IL-34-Dependent Intrarenal and Systemic Mechanisms Promote Lupus Nephritis in MRL-Faslpr Mice.

Authors:  Yukihiro Wada; Hilda M Gonzalez-Sanchez; Julia Weinmann-Menke; Yasunori Iwata; Amrendra K Ajay; Myriam Meineck; Vicki R Kelley
Journal:  J Am Soc Nephrol       Date:  2019-01-08       Impact factor: 10.121

Review 2.  Immunoregulatory properties of the cytokine IL-34.

Authors:  Carole Guillonneau; Séverine Bézie; Ignacio Anegon
Journal:  Cell Mol Life Sci       Date:  2017-03-03       Impact factor: 9.261

3.  Reno-protective effect of IL-34 inhibition on cisplatin-induced nephrotoxicity in mice.

Authors:  Yukihiro Wada; Masayuki Iyoda; Kei Matsumoto; Taihei Suzuki; Shohei Tachibana; Nobuhiro Kanazawa; Hirokazu Honda
Journal:  PLoS One       Date:  2021-01-11       Impact factor: 3.240

4.  Separated parabiont reveals the fate and lifespan of peripheral-derived immune cells in normal and ischaemia-induced injured kidneys.

Authors:  Xuan Deng; Cheng Zhou; Ruichun Liao; Yi Guo; Yuxi Wang; Guoli Li; Jianliang Wu; Huzi Xu; Zhizhi Hu; Guangchang Pei; Wenhui Liao; Ying Yao; Qian Yang; Rui Zeng; Gang Xu
Journal:  Open Biol       Date:  2021-06-09       Impact factor: 6.411

5.  Potential biomarkers for neuroinflammation and neurodegeneration at short and long term after neonatal hypoxic-ischemic insult in rat.

Authors:  Nozha Borjini; Sandra Sivilia; Alessandro Giuliani; Mercedes Fernandez; Luciana Giardino; Fabrizio Facchinetti; Laura Calzà
Journal:  J Neuroinflammation       Date:  2019-10-28       Impact factor: 8.322

6.  IL-34 Actions on FOXP3+ Tregs and CD14+ Monocytes Control Human Graft Rejection.

Authors:  Séverine Bézie; Antoine Freuchet; Céline Sérazin; Apolline Salama; Nadège Vimond; Ignacio Anegon; Carole Guillonneau
Journal:  Front Immunol       Date:  2020-08-11       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.